MT1A and hepatocellular carcinoma: In addition, researchers observed that protein level of MT1 was increased in some patients with HCC taking sorafenib, and found that the phenomenon associated with lower overall survival [34], as well as MT1G could enhance sorafenib resistance via inhibiting ferroptosis in HCC [35].